Pre-Made Ociperlimab biosimilar, Whole mAb, Anti-TIGIT Antibody: Anti-VSIG9/VSTM3/WUCAM therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Pre-made Ociperlimab benchmark antibody ( Whole mAb, anti-TIGIT therapeutic antibody, Anti-VSIG9/VSTM3/WUCAM Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-388
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Products Name (INN Index) | Pre-Made Ociperlimab biosimilar, Whole mAb, Anti-TIGIT Antibody: Anti-VSIG9/VSTM3/WUCAM therapeutic antibody |
---|---|
INN Name | Ociperlimab |
Target | TIGIT |
Format | Whole mAb |
Derivation | NA |
Species Reactivity | Human |
CH1 Isotype | IgG1 |
VD LC | Kappa |
Highest_Clin_Trial (Jan '20) | Phase-III |
Est. Status | Active |
100% SI Structure | None |
99% SI Structure | None |
95-98% SI Structure | None |
Year Proposed | 2020 |
Year Recommended | 2021 |
Companies | BeiGene |
Conditions Approved | NA |
Conditions Active | Non-small cell lung cancer, Cervical cancer, Small-cell lung cancer, Squamous cell cancer, Solid tumours |
Conditions Discontinued | NA |
Development Tech | NA |
Previous Name | NA |
Gm Offical Target Name | TIGIT |
Package |
Genemeidi Omicron Variant Products
test
Previous slide
Next slide